RT-114
Unknown / undisclosed
Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Company guidance: data expected in 2027 (RANI Therapeutics, 9 Nov 2026). “The Phase 1b study will assess the safety, tolerability, and pharmacodynamic effect of eight weeks of repeat dosing with RT-114 in patients with obesity, with data anticipated in 2027.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
No investor-visible indication is recorded for this drug.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (1)
What this study did
Competitive landscape
Other GLP-1/GLP-2 receptor (dual) drugs
dapiglutide, PG-102. Compare all 3 GLP-1/GLP-2 receptor (dual) drugs
2 other tracked programmes target this mechanism, 2 of them ahead of this one.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| RT-114: this drug | Phase 1 | — | GLP-1/GLP-2 receptor (dual) | not yet graded | No reviewed efficacy summary | |
| Dapiglutide | Phase 2(overall) | Peptide | GLP-1/GLP-2 receptor (dual) | Partial signal | NCT05788601: NCT05788601, primary endpoint (% change in body weight, baseline to week 12): 6 mg dapiglutide vs placebo, difference −2.1%; p=0.076. missed | |
| PG-102 | Phase 2(overall) | Protein / enzyme therapeutic | GLP-1/GLP-2 receptor (dual) | Partial signal | Featured results are safety only |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow RT-114 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.